China Blood Product Industry Report, 2015-2018
  • Apr.2015
  • Hard Copy
  • USD $2,650
  • Pages:128
  • Single User License
    (PDF Unprintable)       
  • USD $2,500
  • Code: ZYM064
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $3,800
  • Hard Copy + Single User License
  • USD $2,850

Recombinant blood products have developed for many years in foreign countries, but China’s blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources are the key to the development of Chinese blood product enterprises.

Amid the industrial prosperity and favorable policies, China’s production-use plasma volume broke through 4,000 tons and the total lot release volume jumped by 15% year on year to 52.4 million bottles in 2014. By lot release volume, human albumin, human rabies immunoglobulin, human immunoglobulin (ph4) for intravenous injection and tetanus immunoglobulin were the most popular blood products in China in 2014, accounting for 59.8%, 14.6%, 13.6% and 4.1% of the total lot release volume respectively.

At the same time, the supply and R & D capabilities of human blood coagulation factor VIII, human prothrombin complex and other small products in rigid demand have been intensified in recent years. In 2014, the lot release volume of the above two products ascended by 43.9% and 46.3% year on year respectively. Chengdu Rongsheng, Guangdong Danxia, Yuanda Shuyang, Shanxi Kangbao and other enterprises obtained clinical approval for their human blood coagulation factor VIII in 2014.

Given stringent requirements on new domestic plasma stations, Shanghai RAAS, China Biologic Products (Shandong Taibang and Guizhou Taibang), Hualan Biological Engineering, Tiantan Biological (including Chengdu Rongsheng) and Yuanda Shuyang which boast abundant capital, powerful R&D strength and rich plasma station resources have become the top five companies in China blood product industry, contributing 61.3% to China’s production-use plasma volume and 33.6% to China’s blood product revenue in 2014.

Shanghai RAAS turns to be a Chinese blood product leader through two acquisitions. In 2014, it took over Banghe Pharmaceutical (now known as Zhengzhou RAAS) and TONROL for RMB1.8 billion and RMB4.758 billion separately, so that the blood product varieties of the company increased from 7 to 11, the number of plasma collection stations rose from 12 to 28, and its plasma collection capacity expanded from 400 tons to 900 tons.

?血制品 英文_副本.png

China Blood Product Industry Report, 2015-2018 focuses on the followings:
20120114.gifMarket characteristics, operating environments, status quo, etc. of China blood product industry;
20120114.gifSupply and demand, competitive landscape, import & export, development forecast, etc. of China blood product industry;
20120114.gifSupply and demand, competitive landscape, etc. of 8 blood product segments, including human albumin, human immunoglobulin (pH4) for intravenous injection, blood coagulation factor and tetanus human immunoglobulin.
20120114.gifOperation, blood product business and development prospects of 12 major Chinese blood product companies.

1. Overview of Blood Product Industry
1.1 Definition
1.2 Classification
1.3 Recombinant Blood Products
1.4 Industry Chain
1.5 Features

2. Overview of China Blood Product Industry
2.1 Market Size 
2.2 Status Quo 
2.3 Supply and Demand 
2.3.1 Supply 
2.3.2 Demand 
2.4 Market Competition 
2.5 Operating Environment
2.5.1 International Market
2.5.2 Policy 
2.5.3 Domestic Biopharmaceutical Market
2.6 Import and Export 

3. Blood Product Market Segments in China
3.1 Human Albumin 
3.1.1 Supply and Demand 
3.1.2 Competitive Landscape 
3.1.3 Development Prospect 
3.2 Human Immunoglobulin (pH4) for Intravenous Injection 
3.2.1 Supply and Demand 
3.2.2Competitive Landscape 
3.3 Blood Coagulation Factor VIII 
3.3.1 Supply and Demand 
3.3.2 Competitive Landscape 
3.3.3 Development Prospect 
3.4 Hepatitis B Immunoglobulin 
3.4.1 Supply and Demand 
3.4.2Competitive Landscape 
3.5 Human Immunoglobulin 
3.5.1 Supply and Demand 
3.5.2 Competitive Landscape 
3.6 Human Prothrombin Complex 
3.6.1 Supply and Demand 
3.6.2 Competitive Landscape 
3.7 Tetanus Immunoglobulin 
3.7.1 Supply and Demand 
3.7.2Competitive Landscape 
3.8 Human Rabies Immunoglobulin  
3.8.1 Supply and Demand 
3.8.2 Competitive Landscape 

4. Major Chinese Manufacturers
4.1 China Biologic Products Inc. (NASDAQ: CBPO)
4.1.1 Profile 
4.1.2 Operation 
4.1.3 Revenue Structure  
4.1.4 Customers and Suppliers 
4.1.5 R & D and Investment
4.1.6 Shandong Taibang Biological Products Co., Ltd.
4.1.7 Guizhou Taibang Biological Products Co., Ltd.
4.1.8 Xi'an Huitian Blood Products Co., Ltd.
4.1.9 Prospect and Forecast 
4.2 Hualan Biological Engineering Inc. (002007.SZ)
4.2.1 Profile 
4.2.2 Operation 
4.2.3 Revenue Structure 
4.2.4 Gross Margin 
4.2.5 Customers and Suppliers 
4.2.6 R & D and Investment
4.2.7 Blood Products 
4.2.8 Prospect and Forecast 
4.3 Shanghai RAAS Blood Products Co., Ltd. (002252.SZ)
4.3.1 Profile 
4.3.2 Operation 
4.3.3 Revenue Structure 
4.3.4 Gross Margin 
4.3.5 Customers and Suppliers 
4.3.6 R & D and Investment
4.3.7 Prospect and Forecast 
4.4 Beijing Tiantan Biological Products Co., Ltd. (600161.SH)
4.4.1 Profile 
4.4.2 Operation 
4.4.3 Revenue Structure 
4.4.4 Customers and Suppliers 
4.4.5 Gross Margin 
.4.4.6 R & D and Investment 
4.4.7 Blood Products (Chengdu Rongsheng Pharmaceutical Co., Ltd.)
4.4.8 Prospect and Forecast 
4.5 Zhenxing Biopharmaceutical and Chemical Co., Ltd. (000403.SZ)
4.5.1 Profile 
4.5.2 Operation 
4.5.3 Revenue Structure 
4.5.4 Gross Margin 
4.5.5 Customers and Suppliers 
4.5.6 R & D and Investment 
4.5.7 Blood Products (Guangdong Shuanglin Bio-Pharmacy Co., Ltd.)
4.5.8 Prospect and Forecast 
4.6 Jiangxi Boya Bio-Pharmaceutical Co., Ltd. (300294.SZ)
4.6.1 Profile 
4.6.2 Operation 
4.6.3 Revenue Structure 
4.6.4 Gross Margin 
4.6.5 Customers and Suppliers 
4.6.6 R & D and Investment 
4.6.7 Prospect and Forecast 
4.7 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. 
4.7.1 Profile 
4.7.2 Blood Products 
4.8 Shanghai Institute of Biological Products Co., Ltd. 
4.8.1 Profile 
4.8.2 Blood Products 
4.9 Shanxi Kangbao Biological Product Co., Ltd. 
4.9.1 Profile 
4.9.2 Blood Products 
4.10 Green Cross 
4.10.1 Profile 
4.10.2 Blood Products 
4.11 Humanwell Healthcare Group Co., Ltd. (600079.SH)
4.11.1 Profile 
4.11.2 Operation 
4.11.3 Blood Products (Wuhan Zhongyuan Ruide Biological Product Co., Ltd.)
4.12 Walvax Biotechnology Co, Ltd. (300142.SZ)
4.12.1 Profile 
4. 12.2 Operation 
4.12.3 Blood Products (Hebei Da’an Pharmaceutical Co., Ltd.)

5. Summary and Forecast
5.1 Company Analysis
5.2 Forecast
Basic Composition of Blood
Plasma Protein Separation Procedure
Classification and Efficacy of Blood Products
Comparison between Gene Recombinant Blood Products and Traditional Blood Products
Comparison between Chinese and Overseas Recombinant Blood Products in Types
Blood Product Industry Chain
Time Length of Plasma Collection and Separation Process
Comparison between Blood Product Companies and Chemical & Pharmaceutical Enterprises in Operating Costs and Expenses
Prices of Some Blood Products in China, 2014
Chinese Blood Product Market Size, 2003-2014
Lot Release Volume of Blood Products in China (by Product), 2008-2014
Blood Product Structure in China (by Lot Release Volume), 2009-2014
Annual Production-use Plasma Volume in China, 2002-2014
Geographical Distribution of Plasma Collection Stations in China by the End of 2014
Main Blood Products with Medical Insurance Coverage in China
Comparison between China and Developed Countries in Per Capita Consumption of Blood Products
Plasma Station Distribution, Production-use Plasma Volume and Blood Product Revenue of Major Blood Product Manufacturers in China, 2014
Product Line Comparison between Blood Product Manufacturers in China
Competitive Landscape of Global Blood Product Enterprises, 2013
Product Structure of Global Blood Products
Blood Products Available in Foreign Countries
Global Blood Product Manufacturers
Major Policies on Blood Products in China
Policies on Maximum Retail Prices of Drugs in China, 2014
Lot Release Volume of Imported Human Albumin in China, 2008-2014
Average Human Albumin Purchase Price of Sample Hospitals in China, 2005-2014
Ratio of Domestically-produced to Imported Human Albumin in China (by Lot Release Volume), 2007-2014
Market Share of Major Human Albumin Manufacturers in China (by Lot Release Volume), 2008-2014
Consumption of Human Immunoglobulin (pH4) for Intravenous Injection Per 1,000 People by Country, 2013  
Average Human Albumin Purchase Price of Sample Hospitals in China, 2005-2014
Lot Release Volume and Growth Rate of Human Immunoglobulin (pH4) for Intravenous Injection in China, 2007-2014
Price Comparison between Chinese and Overseas Human Immunoglobulin (pH4) for Intravenous Injection
Market Share of Major Manufacturers of Human Immunoglobulin (pH4) for Intravenous Injection in China (by Lot Release Volume), 2007-2014
Lot Release Volume and Growth Rate of Blood Coagulation Factor VIII in China, 2008-2014 
Market Share of Major Human Blood Coagulation Factor VIII Manufacturers in China (by Lot Release Volume), 2008-2014
Comparison between Human Blood Coagulation Factor VIII and Recombinant Blood Coagulation Factor VIII
Per Capita Consumption of Recombinant VIII Factor and Plasma VIII Factor in Major Countries
Lot Release Volume and Growth Rate of Hepatitis B Immunoglobulin in China, 2009-2014
Market Share of Major Hepatitis B Immunoglobulin Manufacturers in China (by Lot Release Volume), 2008-2014
Prices of Human Immunoglobulin in China by Dosage, 2014
Lot Release Volume and Growth Rate of Human Immunoglobulin in China, 2008-2014 
Market Share of Major Human Immunoglobulin Manufacturers in China (by Lot Release Volume), 2008-2014
Lot Release Volume and Growth Rate of Human Prothrombin Complex in China, 2008-2014
Market Share of Major Human Prothrombin Complex Manufacturers in China (by Lot Release Volume), 2008-2014
Lot Release Volume and Growth Rate of Tetanus Immunoglobulin in China, 2008-2014
Market Share of Major Tetanus Immunoglobulin Manufacturers in China (by Lot Release Volume), 2008-2014
Lot Release Volume and Growth Rate of Human Rabies Immunoglobulin in China, 2008-2014 
Market Share of Major Human Rabies Immunoglobulin Manufacturers in China (by Lot Release Volume), 2008-2014
Equity Structure of China Biologic Products by the End of 2014
Distribution of Blood Product Production Bases and Plasma Stations of China Biologic Products, 2014
Revenue and Operating Income of China Biologic Products, 2007-2014
Gross Margin of China Biologic Products, 2011-2014
Revenue of China Biologic Products by Product, 2011-2014
Revenue Structure of China Biologic Products by Product, 2010-2014
Revenue of China Biologic Products from Top 5 Customers and % of Total Revenue, 2008-2014
R&D Costs and % of Total Revenue of China Biologic Products, 2010-2014
New Products of China Biologic Products under Research by the End of 2014
Lot Release Volume of Blood Products of Shandong Taibang, 2008-2014
Lot Release Volume of Blood Products of Guiyang Qianfeng, 2008-2014
Lot Release Volume of Blood Products of Xi’an Huitian Blood Products, 2008-2014
Revenue and Operating Income of China Biologic Products, 2014-2018E
Revenue and Operating Income of Hualan Biological, 2007-2014
Revenue of Hualan Biological by Sector, 2007-2014
Gross Margin of Hualan Biological by Product, 2007-2014
Revenue of Hualan Biological from Top 5 Customers and % of Total Revenue, 2007-2014
Procurement of Hualan Biological from Top Five Suppliers and % of Total Procurement, 2007-2014
Name List and Procurement of Hualan Biological's Top 5 Suppliers, 2014
R&D Costs and % of Total Revenue of Hualan Biological, 2007-2014
Varieties and Specifications of Blood Products of Hualan Biological
Plasma Collection Station Distribution of Hualan Biological by the End of 2014
Lot Release Volume of Blood Products of Hualan Biological, 2008-2014
Revenue and Gross Margin of Blood Products of Hualan Biological, 2007-2014
Revenue and Gross Margin of Hualan Biological by Product, 2007-2014
Revenue and Operating Income of Hualan Biological, 2014-2018E
Distribution of Plasma Collection Stations of Shanghai RAAS by the End of 2014
Revenue and Operating Income of Shanghai RAAS, 2008-2014
Lot Release Volume of Blood Products of Shanghai RAAS, 2008-2014
Lot Release Volume of TONROL's Blood Products, 2008-2014   
Operating Revenue of Shanghai RAAS by Product, 2008-2014
Revenue of Shanghai RAAS by Region, 2008-2014
Gross Margin of Shanghai RAAS by Product, 2008-2014
Revenue of Shanghai RAAS from Top 5 Customers and % of Total Revenue, 2007-2014
Procurement of Shanghai RAAS from Top 5 Suppliers and % of Total Procurement, 2007-2014
R&D Costs and % of Total Revenue of Shanghai RAAS, 2007-2014
Revenue and Operating Income of Shanghai RAAS, 2014-2018E
Revenue and Profit of Tiantan Biological's Subsidiaries, 2014
Revenue and Operating Income of Tiantan Biological, 2007-2014
Revenue of Tiantan Biological by Sector, 2007-2014
Revenue of Tiantan Biological by Region, 2007-2014
Procurement of Tiantan Biological from Top 5 Suppliers and % of Total Procurement, 2008-2014
Revenue of Tiantan Biological from Top 5 Customers and % of Total Revenue, 2008-2014
Gross Margin of Tiantan Biological by Sector, 2008-2014
R&D Costs and % of Total Revenue of Tiantan Biological, 2009-2014
Distribution of Blood Plasma Collection Stations of Tiantan Biological by the End of 2014
Revenue and Gross Margin of Blood Products of Tiantan Biological, 2007-2014
Lot Release Volume of Blood Products of Chengdu Rongsheng and Tiantan Biological, 2008-2013
Revenue and Operating Income of Tiantan Biological, 2014-2018E
Revenue and Operating Income of Zhenxing Biopharmaceutical and Chemical, 2008-2014
Operating Revenue of Zhenxing Biopharmaceutical and Chemical by Product, 2009-2014
Gross Margin of Zhenxing Biopharmaceutical and Chemical by Product, 2009-2014
Revenue of Zhenxing Biopharmaceutical and Chemical from Top 5 Customers and % of Total Revenue, 2009-2014
Procurement of Zhenxing Biopharmaceutical and Chemical from Top 5 Suppliers and % of Total Procurement, 2013
R&D Costs and % of Total Revenue of Zhenxing Biopharmaceutical and Chemical, 2009-2014
Production-use Plasma Volume of Shuanglin Bio-Pharmacy, 2010-2014
Distribution of Plasma Collection Stations of Shuanglin Bio-Pharmacy by Jun 2014
Lot Release Volume of Blood Products of Shuanglin Bio-Pharmacy, 2008-2014
Revenue and Gross Margin of Blood Products Business of Zhenxing Biopharmaceutical and Chemical, 2009-2014
Revenue and Operating Income of Zhenxing Biopharmaceutical and Chemical, 2014-2018E
Plasma Collection Volume of Jiangxi Boya Bio-Pharmaceutical, 2008-2014 
Revenue and Operating Income of Jiangxi Boya Bio-Pharmaceutical, 2008-2014
Revenue of Jiangxi Boya Bio-Pharmaceutical by Product, 2009-2014
Lot Release Volume of Main Blood Products of Jiangxi Boya Bio-Pharmaceutical, 2011-2014
Operating Revenue of Jiangxi Boya Bio-Pharmaceutical by Region, 2009-2014
Gross Margin of Jiangxi Boya Bio-Pharmaceutical by Product, 2009-2014
Revenue of Jiangxi Boya Bio-Pharmaceutical from Top 5 Customers and % of Total Revenue, 2009-2013
Name List and Revenue Contribution of Top 5 Customers of Jiangxi Boya Bio-Pharmaceutical, 2014
Procurement of Jiangxi Boya Bio-Pharmaceutical from Top 5 Suppliers and % of Total Procurement, 2009-2014
R&D Costs and % of Total Revenue of Jiangxi Boya Bio-Pharmaceutical, 2009-2014
Revenue and Operating Income of Jiangxi Boya Bio-Pharmaceutical, 2014-2018E
Distribution of Blood Plasma Collection Stations of Yuanda Shuyang by the End of 2014
Lot Release Volume of Blood Products of Yuanda Shuyang, 2008-2014
Lot Release Volume of Blood Products of CNBG Shanghai Institute of Biological Products, 2008-2014
Distribution of Blood Plasma Collection Stations of CNBG Shanghai Institute of Biological Products by the End of 2014
Distribution of Blood Plasma Collection Stations of Shanxi Kangbao Biological Product by the End of 2014
Lot Release Volume of Blood Products of Shanxi Kangbao Biological Product, 2008-2014 
Distribution of Blood Plasma Collection Stations of Green Cross China by the End of 2014
Lot Release Volume of Blood Products of Green Cross China, 2008-2014
Revenue and Operating Income of Humanwell Healthcare (Group), 2009-2014
Lot Release Volume of Blood Products of Wuhan Zhongyuan Ruide Biological Product, 2008-2014
Production Industry Layout of Walvax Biotechnology
Revenue and Operating Income of Walvax Biotechnology, 2009-2014
Revenue of Walvax Biotechnology by Sector, 2009-2014
Distribution of Plasma Stations of Major Blood Products Manufacturers in China by Dec 2014
Production-use Plasma Volume of Major Blood Product Manufacturers in China, 2014
Blood Product Revenue of Major Blood Product Manufacturers in China, 2011-2014
Main M & A Cases in China Blood Product Industry, 2008-2014
Chinese Blood Product Market Size, 2013-2018E
Gross Margin of Major Blood Products Manufacturers in China, 2011-2014

China Contract Research Organization (CRO) Industry Report, 2015-2018

In recent years, China's contract research organization (CRO) industry has developed rapidly, with the market size rising from RMB8.5 billion in 2007 to RMB42.6 billion in 2014, registering a CAGR of ...

Global and China Industrial Enzyme Industry Report, 2014-2017

In recent years, the global industrial enzyme preparation market size increased year by year, registering a CAGR of 5%, approximating USD4.2178 billion in 2014. At present, the global industrial enzym...

China Blood Product Industry Report, 2015-2018

Recombinant blood products have developed for many years in foreign countries, but China’s blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources ...

China Human Vaccine Industry Report, 2015-2018

A vaccine is a preventive biological product for human use that prevents and controls the occurrence and prevalence of infectious diseases, so the demand for such products is relatively rigid. Due to ...

China Vacuum Blood Collection Industry Report, 2014-2017

The vacuum blood collection system consisting of vacuum blood collection tubes, disposable blood collection needles, tourniquets, etc transfers human venous blood to closed containers and makes it int...

China Pharmaceutical Excipients Industry Report, 2014-2017

Pharmaceutical excipients refer to adjuvants and additives used for production of pharmaceuticals and compounding of prescriptions. In addition to active ingredients, pharmaceutical excipients are als...

China Recombinant Protein Drug Industry Report, 2014-2017

The Chinese recombinant protein drug market has been expanding rapidly owing to the improvement of demand rigidity, consumption ability and the like. During 2005-2013, sales of recombinant protein dru...

China Heparin Industry Report, 2014-2017

As the world's major heparin API producer and exporter, China boasts enormous raw materials, which provides a strong support for the production of China’s heparin products. In 2013, the live pigs rais...

Global and China Monoclonal Antibody Industry Report, 2014-2019

Despite world-wide economic downturn and great changes in exchange rate, benefiting from robust market demand, global monoclonal antibody market size exceeded USD 80 billion in 2013, still one of biot...

Global and China DNA Sequencing Industry Research Report, 2014-2017

DNA sequencing is the process of reading nucleotide bases in a specific DNA molecule, that is to say determining the arrangement mode of adenine, thymine, cytosine, and guanine. It can be applied in a...

Global and China Stem Cell Industry Report, 2014-2017

Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. Stem cell therapy can be applied to treatmen...

China Human Vaccine Industry Report, 2014-2017

Vaccines can prevent and control infectious diseases, so the demand for these biological products is relatively rigid. In 2013, China’s human vaccine lot release volume grew by 4.9% from a year earlie...

China Blood Product Industry Report, 2014-2017

Plasma resource reserves and control are crucial to the development of blood products industry. Although the closure of 16 plasma collection stations in Guizhou in 2011 didn’t cause major disruption t...

China Animal Vaccine Industry Report, 2013-2016

Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. Europe and the United States and other developed countries are the main ...

China Contract Research Organization (CRO) Industry Report, 2013-2016

China CRO industry has developed rapidly in recent years, registering a CAGR of 27.2% during 2007-2013, of which the market size reached RMB 36 billion in 2013, occupying 10% of global market share. ...

Global and China Biodegradable Plastics Industry Report, 2013-2016

Global biodegradable plastic production and demand have grown rapidly in recent years, and the capacity reached 1-1.5 million t/a in 2012-2013. Among dozens of biodegradable plastic varieties develope...

Global and China Industrial Enzyme Industry Report, 2014-2016

In 2007-2013, the global industrial enzyme market size grew at the CAGR of 5.7%, reaching USD4.04 billion in 2013, 1.4 times that in 2007. The global industrial enzyme market is monopolized by a small...

China Heparin Industry Report, 2013-2015

Since the small intestines of pigs (raw materials for production of heparin) in China are abundant (the pig slaughtering volume in China approximates 50% of globe’s total) and heparin APIs are gradual...

2005-2014 All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号